Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer.
Ravi A. Madan(National Cancer Institute), James L. Gulley(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Julius Strauss(National Cancer Institute), Harpreet Singh(United States Food and Drug Administration), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Guinevere Chun(Center for Cancer Research), Renee N. Donahue(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), Fatima Karzai(National Institutes of Health), Marc R. Theoret(United States Food and Drug Administration), William D. Figg(National Cancer Institute), Anna Couvillon(National Institutes of Health), Christopher R. Heery(National Cancer Institute), Nancy Harold(National Institutes of Health), David G. McLeod(George Washington University), Italia Grenga(National Cancer Institute), Inger L. Rosner, William L. Dahut(National Cancer Institute)
Cited by 6
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817